Coronavirus Disease 2019 (COVID-19): Pipeline and Clinical Trial Analysis – May 2020

Over the coming months, as trial data readouts become available, frontrunners will emerge in both the therapeutic and preventive categories. Currently, the therapeutics space is dominated by candidates already approved for other disease indications; one of these products, an IL-6 inhibitor already marketed for an immunology indication, is well positioned to win the first regulatory approval for COVID-19. The number of clinical trial delays has been steadily increasing throughout Q1 and into Q2 2020. As activity begins to pick up later in the year, trial sponsors might strive to make up for lost time, but the extensive delays will be difficult to overcome entirely.

Scope

Profiles of the most promising treatments and vaccines in the pipeline for COVID-19, including SWOT analyses, an overview of trials, and summaries of available data

An overview of the clinical trials landscape, including discussion of the approaches being adopted for therapeutic and vaccine development

Highlights in deal-making trends, particularly public-private partnerships

Proprietary expert insights on COVID-19 R&D obtained by GlobalData's investigative journalism team

Analysis of the impact of the outbreak on clinical trial timelines across disease areas and geographies

Assessment of regulatory delays associated with the pandemic

GlobalData poll results on topics covered in the report

Reasons to buy

Stay abreast of COVID-19 R&D

Table of Contents

Table of Contents (PowerPoint Deck)

1 Executive Summary

1.1 Report Scope

1.2 Navigate the COVID-19 Outbreak with GlobalData Pharma’s COVID-19 Dashboard

1.3 Monitor the COVID-19 Outbreak with GlobalData Epidemiology Indicators

2 Epidemiology

2.1 Epidemiology: Snapshot as of March 25, 2020

2.2 Epidemiology: Disease Trajectory as of March 25, 2020

2.3 Epidemiology Indicators in the Top 3 Most-Affected Countries: Disease Trajectory in China as of March 25, 2020

2.4 Epidemiology Indicators in the Top 3 Most-Affected Countries: Disease Trajectory in Italy as of March 25, 2020

2.5 Epidemiology Indicators in the Top 3 Most-Affected Countries: Disease Trajectory in the US as of March 25, 2020

2.6 Epidemiology Forecast: United States

3 Pipeline Overview

3.1 Pipeline Therapeutics: Breakdown by Phase

3.2 Pipeline Therapeutics: Breakdown by Molecule Type

3.3 Pipeline Therapeutics: Breakdown by Type of Developer

3.4 Pipeline Therapeutics: Clinical-Stage Candidates (Phase I – III)

3.5 Pipeline Therapeutics: Preclinical-Stage Candidates

3.6 Pipeline Therapeutics: Currently Available Data

3.7 Pipeline Vaccines: Breakdown by Phase

3.8 Pipeline Vaccines: Breakdown by Developer Type

3.9 Pipeline Vaccines: Clinical and Preclinical-Stage Candidates

Pipeline Overview

4.1 Pipeline Therapeutics: Breakdown by Phase

4.2 Pipeline Therapeutics: Breakdown by Molecule Type

4.3 Pipeline Therapeutics: Breakdown by Type of Developer

4.4 Pipeline Therapeutics: Clinical-Stage Candidates (Phase I – III)

4.5 Pipeline Therapeutics: Preclinical-Stage Candidates

4.6 Pipeline Therapeutics: Currently Available Data

4.7 Pipeline Vaccines: Breakdown by Phase

4.8 Pipeline Vaccines: Breakdown by Developer Type

4.9 Pipeline Vaccines: Clinical and Preclinical-Stage Candidates

Clinical Trials

5.1 Clinical Trials: Breakdown by Phase

5.2 Clinical Trials for Therapeutics and Vaccines

5.3 Clinical Trials: Overview by Region

5.4 Clinical Trials for Therapeutics: Leading Sponsors

5.5 Clinical Trials: Leading Industry Sponsors

5.6 Trends in Trial Design

Deal-making Trends

6.1 Deal-making Trends

Social Media Trends

7.1 Key Twitter Chatter

7.2 Top Trending Tweets include #Covid19 #Coronavirus #Patients #Flattenthecurve

Key Findings

8.1 Key Findings

Appendix

9.1 Sources

9.2 Methodology

9.3 About the Authors

About GlobalData

10.1 Contact Us

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports